What is EdiGene?
Founded in 2015 and headquartered in Beijing, China, EdiGene is at the forefront of leveraging advanced genome editing technologies to accelerate the drug discovery pipeline. The company's focus extends to developing innovative therapeutics aimed at addressing a wide spectrum of genetic diseases and oncological conditions. EdiGene's commitment to cutting-edge science positions it as a key player in the rapidly evolving biotechnology landscape, seeking to translate genomic insights into tangible treatment solutions.
How much funding has EdiGene raised?
EdiGene has raised a total of $154.5M across 3 funding rounds:
Series A
$14.5M
Other Financing Round
$11M
Series B
$129M
Series A (2018): $14.5M with participation from Huagai Capital, Lilly Asia Ventures, WI Harper Group, and IDG
Other Financing Round (2019): $11M led by IDG Capital Partners and Lilly Asia Ventures
Series B (2021): $129M supported by Sequoia Capital, Kunlun Capital, Alwin Capital, Sherpa Healthcare Partners, BioTrack Capital, Loyal Valley Capital, Huagai Capital, 3H Health Investment, IDG Capital Partners, and Lilly Asia Ventures
Key Investors in EdiGene
Sequoia Capital
Sequoia Capital is a prominent venture capital firm known for its long-term investment approach and active partnership with entrepreneurs. They have a global track record of investing in leading technology and healthcare companies, focusing on early-stage to late-stage opportunities.
BioTrack Capital
BioTrack Capital is a dedicated healthcare venture capital firm established in 2017, focused on building and incubating innovative life science companies within China. They actively seek out pioneering biotech and medtech ventures led by exceptional entrepreneurs.
Loyal Valley Capital
Loyal Valley Capital, founded in 2015, operates as a thematic, research-oriented private equity firm. They have established themselves as a partner of choice for promising Chinese companies, with a history of backing leading players in various sectors.
What's next for EdiGene?
With the recent influx of major strategic investment and a robust history of significant capital raises, EdiGene is poised for accelerated growth and expansion. This substantial backing is expected to fuel further research and development initiatives, potentially enabling the company to advance its therapeutic candidates through clinical trials and towards market approval. The company's strategic financing indicates a strong market confidence in its technological platform and its potential to address unmet medical needs in genetic diseases and cancer, paving the way for future breakthroughs in precision medicine.
See full EdiGene company page
